SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that Feng Tian, Ph.D., President and Chief Executive Officer of Ambrx, will present at the 30th Annual Virtual Credit Suisse Healthcare Conference on Monday, November 8th, 2021, at 4:20 PM ET.
A live webcast of the presentation will be available online in the “Investor Relations” section of the company’s website at https://ir.ambrx.com/events-and-presentations/events/default.aspx. A replay of the presentation will be available on the company website for 90 days following the webcast.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations, with multiple partners, for drug candidates generated using Ambrx technology. For additional information, please visit www.ambrx.com.